Ben Clevenger1, Kurinchi Gurusamy1, Andrew A Klein2, Gavin J Murphy3, Stefan D Anker4, Toby Richards1. 1. Division of Surgery and Interventional Science, University College London, London, UK. 2. Department of Anaesthesia and Intensive Care, Papworth Hospital, Cambridge, UK. 3. Department of Cardiovascular Sciences and NIHR Cardiovascular Biomedical Research Unit, University of Leicester, and Glenfield General Hospital, Leicester, UK. 4. Department of Innovative Clinical Trials, University Medical Centre Göttingen (UMG), Göttingen, Germany.
Abstract
AIMS: Anaemia is increasingly recognized as having an independent impact upon patient outcomes in cardiac disease. The role of novel iron therapies to treat anaemia is increasing. This systematic review and meta-analysis assesses the efficacy and safety of iron therapies for the treatment of adults with anaemia. METHODS AND RESULTS: Electronic databases and search engines were searched as per Cochrane methodology. Randomized controlled trials (RCTs) of iron vs. inactive control or placebo, as well as alternative formulations, doses, and routes in anaemic adults without chronic kidney disease or in the peri-partum period were eligible. The primary outcome of interest was mortality at 1 year. Secondary outcomes were blood transfusion, haemoglobin levels, quality of life, serious adverse events, and length of hospital stay. A total of 64 RCTs (including five studies of heart failure patients) comprising 9004 participants were included. None of the studies was at a low risk of bias. There were no statistically significant differences in mortality between iron and inactive control. Both oral and parenteral iron significantly reduced the proportion of patients requiring blood transfusion compared with inactive control [risk ratio (RR) 0.66, 95% confidence interval (CI) 0.48-0.90; and RR 0.84, 95% CI 0.73-0.97, respectively]. Haemoglobin was increased more by both oral and parenteral iron compared with inactive control [mean difference (MD) 0.91 g/dL, 95% CI 0.48 to 1.35; and MD 1.04, 95% CI 0.52 to 1.57, respectively], and parenteral iron demonstrated a greater increase when compared with oral iron (MD 0.53 g/dL, 95% CI 0.31-0.75). In all comparisons, there were no differences in the results comparing patients with and without heart failure. CONCLUSION: Both oral and parenteral iron are shown to decrease the proportion of people who require blood transfusion and increase haemoglobin levels, without any benefit on mortality. Further trials at a low risk of bias, powered to measure clinically significant endpoints, are still required.
AIMS: Anaemia is increasingly recognized as having an independent impact upon patient outcomes in cardiac disease. The role of novel iron therapies to treat anaemia is increasing. This systematic review and meta-analysis assesses the efficacy and safety of iron therapies for the treatment of adults with anaemia. METHODS AND RESULTS: Electronic databases and search engines were searched as per Cochrane methodology. Randomized controlled trials (RCTs) of iron vs. inactive control or placebo, as well as alternative formulations, doses, and routes in anaemic adults without chronic kidney disease or in the peri-partum period were eligible. The primary outcome of interest was mortality at 1 year. Secondary outcomes were blood transfusion, haemoglobin levels, quality of life, serious adverse events, and length of hospital stay. A total of 64 RCTs (including five studies of heart failurepatients) comprising 9004 participants were included. None of the studies was at a low risk of bias. There were no statistically significant differences in mortality between iron and inactive control. Both oral and parenteral iron significantly reduced the proportion of patients requiring blood transfusion compared with inactive control [risk ratio (RR) 0.66, 95% confidence interval (CI) 0.48-0.90; and RR 0.84, 95% CI 0.73-0.97, respectively]. Haemoglobin was increased more by both oral and parenteral iron compared with inactive control [mean difference (MD) 0.91 g/dL, 95% CI 0.48 to 1.35; and MD 1.04, 95% CI 0.52 to 1.57, respectively], and parenteral iron demonstrated a greater increase when compared with oral iron (MD 0.53 g/dL, 95% CI 0.31-0.75). In all comparisons, there were no differences in the results comparing patients with and without heart failure. CONCLUSION: Both oral and parenteral iron are shown to decrease the proportion of people who require blood transfusion and increase haemoglobin levels, without any benefit on mortality. Further trials at a low risk of bias, powered to measure clinically significant endpoints, are still required.
Authors: Toby Richards; Ravishankar Rao Baikady; Ben Clevenger; Anna Butcher; Sandy Abeysiri; Marisa Chau; Rebecca Swinson; Tim Collier; Matthew Dodd; Laura Van Dyck; Iain Macdougall; Gavin Murphy; John Browne; Andrew Bradbury; Andrew Klein Journal: Health Technol Assess Date: 2021-02 Impact factor: 4.014
Authors: Stephan von Haehling; Uwe Gremmler; Michael Krumm; Frank Mibach; Norbert Schön; Jens Taggeselle; Johannes B Dahm; Christiane E Angermann Journal: Clin Res Cardiol Date: 2017-02-22 Impact factor: 5.460
Authors: Akshay Shah; Anita Sugavanam; Jack Reid; Antony J Palmer; Edward Dickson; Susan Brunskill; Carolyn Doree; Charles M Oliver; Austin Acheson; Ravi Rao Baikady; Sohail Bampoe; Edward Litton; Simon Stanworth Journal: BMJ Open Date: 2019-06-04 Impact factor: 2.692
Authors: Akshay Shah; Noémi B Roy; Stuart McKechnie; Carolyn Doree; Sheila A Fisher; Simon J Stanworth Journal: Crit Care Date: 2016-09-29 Impact factor: 9.097
Authors: Thomas Drabinski; Kai Zacharowski; Patrick Meybohm; Alexandra M Rüger; Antonio Ramirez de Arellano Journal: Adv Ther Date: 2020-06-19 Impact factor: 3.845